INDV
Indivior PLC Ordinary SharesNASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$3.81B
P/E Ratio
18.58
EPS
$1.64
Beta
1.21
52W High
$38.00
52W Low
$8.69
50-Day MA
$32.48
200-Day MA
$27.56
Dividend Yield
—
Profit Margin
17.00%
Forward P/E
10.24
PEG Ratio
—
About Indivior PLC Ordinary Shares
Indivior PLC, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company is headquartered in North Chesterfield, Virginia.
Fundamentals
| Revenue (TTM) | $1.24B |
| Gross Profit (TTM) | $1.04B |
| EBITDA | $397.00M |
| Operating Margin | 37.10% |
| Return on Equity | 12.20% |
| Return on Assets | 19.20% |
| Revenue/Share (TTM) | $9.91 |
| Book Value | $-0.78 |
| Price-to-Book | 145.25 |
| Price-to-Sales (TTM) | 3.08 |
| EV/Revenue | 3.125 |
| EV/EBITDA | 12.74 |
| Quarterly Earnings Growth (YoY) | 376.20% |
| Quarterly Revenue Growth (YoY) | 19.70% |
| Shares Outstanding | $121.92M |
| Float | $106.43M |
| % Insiders | 1.39% |
| % Institutions | 90.92% |
Analyst Ratings
Consensus ($46.86 target)
2
Strong Buy5
BuyData last updated: 4/8/2026